← Leaderboards
Marsha A Moses
Children'S Hospital Boston
$6,062,315
Attributed
$6,645,645
Total exposure
13
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $600.6K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,645,645 · 13
By mechanism
R01$3,641,739 · 3
U01$1,166,660 · 1
R21$910,223 · 2
P50$626,378 · 5
P01$300,645 · 2
Top collaborators
- Richard Sang-Yong Lee5 shared
Most similar at Children'S Hospital Boston
Same institution · by research overlap
- Bruce R Zetter$9,054,208
- Judah Folkman$11,710,747
- Michael Klagsbrun$9,114,200
- Michael W Fannon$1,415,322
- Donald E Ingber$21,971,527
Others in their field
Top investigators on “Phenotype”
- David R. Weir · University Of Michigan At Ann Arbor$239,033,262
- David Heimbrook · Leidos Biomedical Research, Inc.$213,586,034
- Constance Ann Benson · University Of California, San Diego$187,132,366
- Richard A Gibbs · Baylor College Of Medicine$184,906,270
- James E. Gern · University Of Wisconsin-Madison$141,704,104
- Garret A Fitzgerald · University Of Pennsylvania$141,348,491
Research focus
PhenotypeProteinsRegulationAngiogenesisUrinaryDiagnosticProgramsPrognosticMalignant NeoplasmsGrowthIn VivoTumorMediatingBiological MarkersMultidisciplinaryAnimal ModelNovel TherapeuticsMolecularTumor GrowthClinically RelevantInterestTreatment EfficacyTumor ProgressionUrine
Grant awards (28)
Engineered exosome mimetics as targeted biological nanomedicines for pancreatic cancer$206,869
R21 · FY2025 · CA · contact PI
Engineered exosome mimetics as targeted biological nanomedicines for pancreatic cancer$248,243
R21 · FY2024 · CA · contact PI
Molecular mechanisms of extracellular vesicle-derived modulation of transcytosis at the blood brain barrier$455,111
R21 · FY2020 · CA · contact PI
Discovery, Validation and Clinical Application of Novel, Non-Invasive Biomarkers$233,332
U01 · FY2018 · DK · contact PI
(PQA2): Escape from breast tumor dormancy: convergence of obesity and menopause$367,275
R01 · FY2017 · CA · contact PI
Discovery, Validation and Clinical Application of Novel, Non-Invasive Biomarkers$233,332
U01 · FY2017 · DK · contact PI
(PQA2): Escape from breast tumor dormancy: convergence of obesity and menopause$367,275
R01 · FY2016 · CA · contact PI
Discovery, Validation and Clinical Application of Novel, Non-Invasive Biomarkers$233,332
U01 · FY2016 · DK · contact PI
(PQA2): Escape from breast tumor dormancy: convergence of obesity and menopause$366,410
R01 · FY2015 · CA · contact PI
Discovery, Validation and Clinical Application of Novel, Non-Invasive Biomarkers$233,332
U01 · FY2015 · DK · contact PI
(PQA2): Escape from breast tumor dormancy: convergence of obesity and menopause$364,336
R01 · FY2014 · CA · contact PI
Discovery, Validation and Clinical Application of Novel, Non-Invasive Biomarkers$233,332
U01 · FY2014 · DK · contact PI
Molecular regulation of breast cancer growth$291,276
R01 · FY2010 · CA · contact PI
Molecular regulation of breast cancer growth$291,276
R01 · FY2009 · CA · contact PI
Molecular regulation of breast cancer growth$291,276
R01 · FY2008 · CA · contact PI
Molecular regulation of breast cancer growth$291,276
R01 · FY2007 · CA · contact PI
The Harvard Urologic Research Cener$216,832
P50 · FY2007 · DK · contact PI
Molecular regulation of breast cancer growth$299,975
R01 · FY2006 · CA · contact PI
PROJECT 3$214,689
P50 · FY2006 · DK · contact PI
PROJECT 3$194,857
P50 · FY2005 · DK
PROJECT 3$0
P50 · FY2004 · DK
TIMPs as Modular Inhibitors of Angiogenesis$0
P50 · FY2003 · DK
NOVEL ANGIOGENESIS INHIBITOR FROM CARTILAGE$244,164
R01 · FY2002 · CA
Molecular regulation of angiogenesis during tumor progression$0
P01 · FY2002 · CA
NOVEL ANGIOGENESIS INHIBITOR FROM CARTILAGE$237,052
R01 · FY2001 · CA
PROTEASE/ANTIPROTEASE BALANCE--ROLE IN ANGIOGENESIS$91,598
P01 · FY2001 · CA
NOVEL ANGIOGENESIS INHIBITOR FROM CARTILAGE$230,148
R01 · FY2000 · CA
PROTEASE/ANTIPROTEASE BALANCE--ROLE IN ANGIOGENESIS$209,047
P01 · FY2000 · CA